Integra LifeSciences Holdings Corp. 8-K Summary
Business Context and Reporting Period
Integra LifeSciences Holdings Corporation (Nasdaq: IART) filed a Current Report on Form 8-K on February 26, 2026. The filing announces financial results for the quarter and full year ended December 31, 2025. The report incorporates a press release (Exhibit 99.1) containing GAAP and non-GAAP financial data.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It confirms that the attached press release contains reconciliations for the following metrics for the periods ended December 31, 2025 and 2024:
- GAAP revenues to organic revenues.
- GAAP net income to adjusted EBITDA and adjusted net income.
- GAAP gross profit and margin to adjusted gross profit and margin.
- GAAP earnings per diluted share to adjusted earnings per diluted share.
- GAAP total debt to net debt.
- GAAP operating cash flow to free cash flow and adjusted free cash flow conversion.
Material Changes and Adjustments
Management utilizes non-GAAP measures to exclude items that vary significantly or are non-cash in nature. Key adjustments described in the filing include:
- Structural Optimization: Severance, facility exit costs, and infrastructure rationalization.
- M&A Activity: Acquisition, divestiture, and integration-related charges, including inventory fair value adjustments.
- Regulatory and Operational: EU Medical Device Regulation compliance costs and charges related to the 2023 Boston facility recall and transition to Braintree, Massachusetts.
- Non-Cash Items: Intangible asset amortization and impairment charges (noted as related to tariff uncertainty and quality/supply issues).
Guidance, Outlook, and Risks
The Company provided forward-looking guidance for organic revenues and adjusted earnings per diluted share. However, it did not provide reconciliations to forward-looking GAAP measures due to the high variability of certain GAAP expense items and foreign exchange impacts.
Risks and Contingencies:
- Foreign Exchange: Significant revenue generation outside the U.S. creates exposure to currency fluctuations.
- Acquisition Costs: Future M&A activity may incur significant expenses or aborted deal costs.
- Regulatory Compliance: Ongoing costs associated with EU Medical Device Regulations.
- Operational Disruptions: Historical impacts from manufacturing recalls and facility transitions.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific numerical values of revenue, net income, and cash flow, as they are not present in the 8-K text.
- Verify the reconciliation tables to understand the magnitude of non-GAAP adjustments, specifically regarding impairment charges and recall-related costs.
- Assess the impact of foreign exchange rates on organic revenue growth versus reported GAAP revenue.
- Confirm the specific forward-looking guidance ranges for adjusted earnings per diluted share provided in the press release.
- Monitor updates on the transition of manufacturing operations from Boston to Braintree and any residual costs.